- Home
- SLS
as 11-15-2024 4:00pm EST
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 75.3M | IPO Year: | N/A |
| Target Price: | $3.00 | AVG Volume (30 days): | 753.9K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $1.72 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest SELLAS Life Sciences Group Inc. News
SLS Breaking Stock News: Dive into SLS Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate
GlobeNewswire
4 days ago
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
12 days ago
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
MT Newswires
a month ago
SELLAS Life Sciences Gets FDA Rare Pediatric Disease Designation for Acute Myeloid Leukemia Immunotherapy
GlobeNewswire
a month ago
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
GlobeNewswire
a month ago
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Insider Monkey
2 months ago
Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory
GlobeNewswire
3 months ago
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Compare SLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLS SELLAS Life Sciences Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.